Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The role of myeloma B-cells & pre-plasma cell progenitors in disease relapse following therapy

Rodger Tiedemann • 27 Sep 2023
IMS 2023
Multiple Myeloma

Rodger Tiedemann, MD, PhD, FRACP, FRCPA, Princess Margaret Cancer Centre, Toronto, Canada, shares some insights into a study which evaluated the role of myeloma B-cells and pre-plasma progenitor cells in disease relapse using whole exome sequencing (WES) and extensive mutational profiling. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Janssen, AbbVie

More from Rodger Tiedemann

2:28
B-cells and pre-plasma cells are important reservoirs responsible for relapse in multiple myeloma
Rodger Tiedemann • 9 Dec 2023
12:10
Using single-cell analysis to tackle myeloma
Eileen Boyle et al. • 26 Mar 2022
10:54
Optimism for the use of liquid biopsies in multiple myeloma
Andrew Spencer et al. • 18 Oct 2017

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals